Crizotinib: a new treatment option for non-small cell lung cancer
What is Crizotinib? Crizotinib (Xalkori) is a targeted therapy approved by the FDA for treatment of patients with advanced ALK-positive non-small cell lung cancers who have progressed after prior chemotherapy. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses. The majority of these tumors contain activating mutations in the anaplastic lymphoma …
Crizotinib: a new treatment option for non-small cell lung cancer Read More »